Table 2.
Demographic characteristics for initially enrolled participants and subset.
| Total (N = 37) | Subset (n = 7) | |
|---|---|---|
| Gender, n (%) | ||
| Male | 15 (40.5) | 4 (57.15) |
| Female | 22 (59.5) | 3 (42.85) |
| Age, M (SD) | 35.6 (10.8) | 36.3 (9.19) |
| Min, Max | 18.6, 62.3 | 23, 50 |
| Ethnicity, n (%) | ||
| American Indian | 1 (2.7) | 0 |
| or Alaskan native | ||
| Asian | 6 (16.2) | 1 (14.3) |
| Black | 1 (2.7) | 0 |
| White | 27 (73.0) | 6 (85.7) |
| Multiple | 2 (5.4) | 0 |
| Type of trauma, n (%) | ||
| Developmental trauma | 29 (78.4) | 5 (71.4) |
| Veteran | 5 (15.2) | 2 (28.6) |
| Combat exposure | 3 (9.1) | 2 (28.6) |
| Multiple trauma | 27 (81.8) | 4 (57.1) |
| CAPS-5, baseline (n = 37), M (SD) | 45.4 (7.18) | 46.28 (5.72) |
| Change in CAPS-5, baseline to termination (n = 36), M (SD) | −29.89 (13.45) | −34 (15.71) |
One participant withdrew from the trial before to the onset of the second MDMA-AP session due to a mild increase of nightmares. This individual was the only one who did not complete the primary endpoint evaluation.